Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by analysts at Laidlaw from a “hold” rating to a “buy” rating in a research report issued on Monday, The Fly reports.
ICPT has been the subject of several other research reports. ValuEngine downgraded Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 8th. Wedbush set a $220.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 6th. BidaskClub cut shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $113.00 price target for the company in a report on Tuesday, November 13th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $170.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, December 6th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals has an average rating of “Buy” and an average price target of $152.13.
NASDAQ ICPT opened at $109.73 on Monday. Intercept Pharmaceuticals has a 12 month low of $51.05 and a 12 month high of $133.74. The company has a market cap of $3.35 billion, a price-to-earnings ratio of -7.63 and a beta of -0.68. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.65) by $0.47. The firm had revenue of $47.00 million for the quarter, compared to analysts’ expectations of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted ($2.89) earnings per share. As a group, analysts expect that Intercept Pharmaceuticals will post -10.32 earnings per share for the current year.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $101.07, for a total value of $5,053,500.00. Following the sale, the chief executive officer now owns 589,199 shares in the company, valued at approximately $59,550,342.93. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Lisa Bright sold 1,313 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $104.93, for a total value of $137,773.09. Following the completion of the sale, the insider now owns 18,807 shares in the company, valued at approximately $1,973,418.51. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 814,130 shares of company stock worth $85,352,325. 4.90% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Intercept Pharmaceuticals in the 3rd quarter worth approximately $126,000. Chicago Equity Partners LLC purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at approximately $215,000. GWM Advisors LLC purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at approximately $220,000. United Services Automobile Association purchased a new stake in shares of Intercept Pharmaceuticals in the second quarter valued at approximately $280,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at approximately $293,000. Institutional investors and hedge funds own 63.62% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.
Featured Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.